Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul;24(7):908-922.
doi: 10.1038/s41591-018-0104-9. Epub 2018 Jul 2.

Mechanisms of NAFLD development and therapeutic strategies

Scott L Friedman  1 , Brent A Neuschwander-Tetri  2 , Mary Rinella  3 , Arun J Sanyal  4
Affiliations
Review

Mechanisms of NAFLD development and therapeutic strategies

Scott L Friedman et al. Nat Med. 2018 Jul.

Abstract

There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD), paralleling a worldwide increase in diabetes and metabolic syndrome. NAFLD, a continuum of liver abnormalities from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), has a variable course but can lead to cirrhosis and liver cancer. Here we review the pathogenic and clinical features of NAFLD, its major comorbidities, clinical progression and risk of complications and in vitro and animal models of NAFLD enabling refinement of therapeutic targets that can accelerate drug development. We also discuss evolving principles of clinical trial design to evaluate drug efficacy and the emerging targets for drug development that involve either single agents or combination therapies intended to arrest or reverse disease progression.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare no competing interests.

Figures

Fig. 1|
Fig. 1|. The substrate-overload liver injury model of NASH pathogenesis.
Free fatty adds are central to the pathogenesis of NASH. Free fatty adds that originate from lipolysis of triglyceride in adipose tissue are delivered through blood to the liver. The other major contributor to the free fatty acid flux through the liver is DNL, the process by which hepatocytes convert excess carbohydrates, especially fructose, to fatty acids. The two major fates of fatty acids in hepatocytes are mitochondrial beta-oxidation and re-esterification to form triglyceride. Triglyceride can be exported into the blood as VLDL or stored in lipid droplets. Lipid droplet triglyceride undergoes regulated lipolysis to release fatty acids back into the hepatocyte free fatty acid pool. PNPLA3 participates in this lipolytic process, and a single-nucleotide variant of PNPLA3 is strongly associated with NASH progression, underscoring the importance of the regulation of this lipolysis. When the disposal of fatty acids through beta-oxidation or formation of triglyceride is overwhelmed, fatty acids can contribute to the formation of lipotoxic species that lead to ER stress, oxidant stress and inflammasome activation. These processes are responsible for the phenotype of NASH with hepatocellular injury, inflammation, stellate cell activation and progressive accumulation of excess extracellular matrix. Lifestyle modifications that include healthy eating habits and regular exercise reduce the substrate overload through decreased intake and diversion of metabolic substrates to metabolically active tissues and can thereby prevent or reverse NASH. SCD, steroyl CoA-desaturase; FAS, fatty acid synthase; NKT, natural killer T cell; Tregs, regulatory T cells; PMNs, polymorphonuclear leukocytes. Credit: Marina Corral Spence/Springer Nature
Fig. 2|
Fig. 2|. Intrahepatic drug targets in phase 2 and 3 clinical trials for NASH.
Depiction of the sites of action of drugs that are currently in phase 2 or 3 clinical trials, based on their primary locus of activity within the liver. Targets include those that regulate lipids and glucose homeostasis, and oxidant stress and mitochondrial targets in hepatocytes, inflammatory signals converge on hepatocytes, and those inflammatory signals and intracellular targets related to stellate cell activation and fibrogenesis. Gray boxes indicate disease drivers. Some targets (e.g, FXR agonists, CCR2 and CCR5 (CCR2/5) antagonist) have more than one action within the injury milieu. Agonists are indicated with a circle and antagonists with a cross. DGAT, Diacylglycerol O-acyltransferase; SCD, steroyl CoA-desaturase; THR, thyroid hormone receptor; SIRT, sirtuin; GLP, glucagon-like peptide; SGLT, sodium–glucose cotransporter; VAP, vascular adhesion protein; LPS, lipopolysaccharide; PPARα/δ/γ, peroxisome proliferator–activated receptors PPARα, PPARδ and PPARγ. Credit: Marina Corral Spence/Springer Nature
None
Histologic features of human NASH.
a, A schema for diagnosing NAFLD and NASH. Credit: Marina Corral Spence/Springer Nature. b, The panel of images from liver biopsies demonstrate the typical appearances of macrovesicular steatosis (fat), hepatocellular ballooning, lobular inflammation and pericellular fibrosis (arrows). As the disease progresses into cirrhosis (not shown), these features may also regress. H&E staining images were courtesy of Pierre Bedossa)
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Estes C, Razavi H, Loomba R, Younossi Z & Sanyal AJ Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67, 123–133 (2018). - PMC - PubMed
    1. Younossi ZM et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64, 1577–1586 (2016). - PubMed
    1. Goldberg D et al. Changes in the Prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 152, 1090–1099 (2017). - PMC - PubMed
    1. Wong RJ et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148, 547–555 (2015). - PubMed
    1. Mittal S et al. Hepatocellular carcinoma in the absence of cirrhosis in united states veterans is associated with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol 14, 124–131.e1 (2016). - PMC - PubMed